ArticleFrontiers in neurology2026
Exploratory proteomic biomarker combinations associated with post-concussion symptoms following a concussion in adolescents.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Objective: This study examined the ability of established brain biomarkers, glial fibrillary acid protein (GFAP), neuro-filament light chain (NFL), ubiquitin carboxy hydrolase-L1(UCH-L1), tau, and phosphorylated tau (p-tau), and novel biomarkers from blood collected sub-acutely after concussion to determine prediction of persisting post-concussion symptoms (PPCS) beyond 3 months. We hypothesized that a combination of established and novel proteins would predict high PPCS burden. Participants: Adolescents 11 to 17.99 years with a concussion based on Concussion In Sport Group (CISG) criteria were eligible. Participants were assessed 7-35 days post-injury (baseline) and then reassessed at 3 months (follow-up) for persistent post-concussion symptoms (PPCS) using the Post-Concussion Symptom Inventory, 2nd Edition (PCSI-2). A total of 155 participants (78 females, 77 males) with both blood biomarkers and 3-month symptom data were analyzed. Design: Plasma proteins collected sub-acutely (7-35 days post concussion) were quantified by both Quanterix and the Olink Explore platform, and compared between participants with the highest and lowest quartiles of PPCS severity at follow-up (85-95 days post concussion) using the PCSI-2. An exhaustive best-subsets logistic regression strategy was executed following clinical and biological pre-filtering to identify parsimonious multivariable configurations of protein biomarkers distinguishing individuals with high and low PPCS at follow-up. A stratified 10-fold cross-validation framework was implemented to evaluate model generalizability and safeguard against overfitting, while bootstrapping was used to calculate confidence intervals. Ingenuity Pathway Analysis (IPA) was performed to generate hypotheses of molecular pathways implicated in PPCS pathogenesis. Results: None of the brain biomarkers collected sub-acutley were significantly different in PPCS-high and PPCS-low groups at 90-day follow-up. No Olink proteins survived multiple testing correction, but a cross-validated multivariable model, including Tripartite Motif Containing 39 (TRIM39) + Sclerostin (SOST) + Transcription factor Dp family member 3 (TFDP3) + TNF receptor superfamily member 9 (TNFRSF9) + Leptin (LEP) + Prune Homolog 2 With BCH Domain (PRUNE2) + Trimethylguanosine Synthase 1 (TGS1) + EPCAM (Epithelial Cell Adhesion Molecule) distinguished high PPCS at follow-up with an area under the curve (AUC) of 0.86 (95% CI 0.80-0.92). IPA identified three significant networks associated with PPCS: (a) cardiovascular and neurological disease, organismal injury, and abnormalities (score = 45; 28 focus molecules); (b) connective tissue disorders, inflammatory disease, and organismal injury and abnormalities (score = 41; 26 focus molecules); and (c) connective tissue development and function, embryonic development, and organismal development (score = 41; 26 focus molecules). Conclusion: This study suggests the possibility to utilize novel biomarkers discovered by high throughput proteomic analysis to predict high PPCS. Future research should further develop precision of unique biomarker profiles and prolonged symptomatology in adolescents' post-concussion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.